Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Based on the provided context, "Shenyu" is most prominently associated with "Shenyu Ningshen tablet", which is described as the first pure Chinese medicinal small compound preparation approved for clinical trials in China for the treatment of depression. This tablet has shown significant efficacy in improving depression symptoms, particularly those related to qi and yin deficiency. Its mechanism involves anti-inflammatory and neuroprotective effects, achieved by inhibiting A1-reactive astrocytes and neuroinflammatory factors within the hippocampus. The user's prompt also links "Shenyu" to the Chinese name "参榆灌肠液" (Shenyu Enema Solution), but no specific information about this enema solution is available in the provided context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenyu.